FDA delays Botox alternative Reloxin
The US Food and Drug Administration (FDA) has delayed approving Botox alternative Reloxin while it discusses labelling and risk mitigation with the manufacturers of the drug, Medicis Pharmaceutical Corp and Ipsen SA.
The FDA is expected to delay Reloxin to market until later this year, questioning how the manufacturers plan to track the use of the product to minimise potential risks.
Reloxin will likely be priced at 15% lower than Botox, leading analysts to predict that annual sales of the product will reach $160m by 2012.
Join this Discussion
